cid1450 - Physician's Weekly


Advertisement

cid1450

SABCS 2020 eBook

SABCS Conference Report Featured: Update on Novel Agent from the DESTINY-Breast01 Trial How to Avoid Chemotherapy Overtreatment in Breast Cancer First Immunotherapy Combo Well-Tolerated Phase 3 MonarchE Trial: Efficacy...

SABCS 2020: First Immunotherapy Combo Well-Tolerated

In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...

SABCS 2020: Update from the DESTINY-Breast01 trial

In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...

Loading

Advertisement

For latest news and updates
Email-id is invalid